Hoth Therapeutics, Inc. States COVID-19 Coronavirus Poses No Negative Effect on Company's Operations

NEW YORK, March 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. HOTH a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, announced today that its business operations have not been affected by COVID-19 Coronavirus.

Mr. Robb Knie, CEO of Hoth Therapeutics, Inc. stated, "Hoth continues its plans for an upcoming trial in Australia later this year for its proprietary BioLexa Platform for those patients suffering with mild to moderate atopic dermatitis.  Our preclinical study of WEG-232 for dermatological treatment relating to the side effects of cancer medication is in its final stages and we look forward to sharing those results later this month.  The VNLG-152 preclinical study at Weill Cornell Medicine to examine the efficacy of RAMBA in blocking acne pathogenic gene expression and carcinogenesis in mice is well underway and continuing to proceed.  Our Gene Therapy program in conjunction with N.C. State has progressed to its next steps with no interruptions.  We at Hoth look forward to further updating our shareholders as we continue to work diligently to further the development of therapeutics within our pipeline."

While the Company does not anticipate that the virus poses any interruptions to its business or its clinical trial timeline, it did offer a reminder to those patients that are afflicted with Atopic Dermatitis.  The National Eczema Society stated that there is currently no "eczema-friendly" hand sanitizer on the market, as those available products all contain alcohol.  Overuse of the product can cause increased dryness to patients' skin, therefore causing cracks and increasing potential points of entry for viruses.  Hoth stands with the National Eczema Society and would like to provide this reminder in an effort to increase awareness and improve public safety. For more information please visit: http://www.eczema.org/coronavirus.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Contacts
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com 
www.hoththerapeutics.com

KCSA Strategic Communications
Valter Pinto, Managing Director 
(212) 896-1254
Hoth@kcsa.com

SOURCE Hoth Therapeutics, Inc.